UK-453,061 (lersivirine), a Pfizer drug now being developed by ViiV Healthcare, is a second-generation NNRTI. It does not seem to have a significant effect on CYP3A4 metabolic activity and  appears to be active against the common NNRTI mutations. It is enrolling patients into a phase II study comparing UK-453,061 to efavirenz, both taken with Truvada.1


  1. Fatkenheuer G et al. Short-term monotherapy with UK-453,061, a novel NNRTI, reduces viral load in HIV-infected patients. Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, abstract WESS202, 2007
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap